hepatoАнналы хирургической гепатологииAnnaly khirurgicheskoy gepatologii = Annals of HPB Surgery1995-54642408-9524НЭИКОН ИСП10.16931/1995-5464.2020485-94hepato-628Research ArticleПЕЧЕНЬLIVERГепатоцеллюлярный рак у детей - основные отличия от взрослых пациентовPediatric hepatocellular carcinoma - the main differences from adult patientshttps://orcid.org/0000-0002-1387-209XАхаладзеД. Г.AkhaladzeD. G.

Ахаладзе Дмитрий Гурамович – канд. мед. наук, руководитель группы торакоабдоминальной хирургии

117997, Москва, ул. Саморы Машела, д. 1, Тел.: 8-905-587-89-92

Dmitry G. Akhaladze – Cand. of Sci. (Med.), Head of Thoracoabdominal Surgery Group

1, Samory Mashela str., Moscow, 117997, Phone: 8-905-587-89-92

d.g.akhaladze@gmail.comhttps://orcid.org/0000-0002-5691-2522РабаевГ. С.RabaevG. S.

Рабаев Гавриил Савельевич – врач – детский хирург отделения онкологии и детской хирургии

117997, Москва, ул. Саморы Машела, д. 1

Gavriil S. Rabaev – Resident of the Department of Pediatric Oncology and Surgery

117997, Moscow, 1 Samory Mashela str.

rabaevgesha@gmail.comФГБУ "НМИЦ детской гематологии, онкологии и иммунологии им. Дмитрия Рогачёва" Минздрава РоссииРоссияDmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology Ministry of Health of Russian FederationRussian Federation2020091120202548594Copyright © Ахаладзе Д.Г., Рабаев Г.С., 20202020Ахаладзе Д.Г., Рабаев Г.С.Akhaladze D.G., Rabaev G.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://hepato.elpub.ru/jour/article/view/628

Цель: сравнить особенности гепатоцеллюлярного рака у детей и взрослых, а также оценить возможность экстраполяции опыта лечения взрослых пациентов на педиатрическую практику. Материал и методы. Проведен анализ литературы, посвященной изучению и лечению гепатоцеллюлярного рака у детей и взрослых. Отдельное внимание уделено сравнению патоморфологических и молекулярно-генетических особенностей болезни и подходов к медикаментозному и хирургическому лечению, в частности иммунотерапии и трансплантации печени. Результаты. Для гепатоцеллюлярного рака у детей характерно превалирование фиброламеллярного гистологического подтипа, наличие характерных молекулярно-генетических маркеров, большие размеры первичной опухоли. У детей целесообразно применять методы лечения, заимствованные у взрослых, – таргетную и иммунотерапию. Подходы к хирургическому лечению, в частности показания к трансплантации печени, у детей должны отличаться. Заключение. Дальнейший перенос опыта лечения взрослых пациентов на детскую популяцию позволит улучшить результаты лечения детей с гепатоцеллюлярным раком. Работа в рамках международных исследовательских групп необходима для оптимизации лечения детей с гепатоцеллюлярным раком.

Aim

Aim: to compare features of hepatocellular carcinoma (HCC) in children and adult patients and to assess the possibility of translating the experience of adult patients treating  in pediatric oncology.

Мethods

Мethods: the literature dedicated to pediatric and adult HCC investigation and treatment has been analyzed. Pathomorphology, molecular-genetic features of disease, the drug and surgical  treatment approaches, in particular immunotherapy and liver transplantation  were carefully compared in both groups.

Results

Results: for pediatric HCC the analysis revealed that: fibrolamellar subtype as well as large size of primary tumor are more common; typical molecular-genetic markers are presented. It is advisable to use the adopted adults treatment methods such as targeted and immunotherapy in children. In particular, the HCC surgery, and the indications for liver transplantation in children should be different from adults.

Conclusion

Conclusion: further translation of the adult patients treating experience will help to improve outcome in children with HCC. In order to optimize the treatment of pediatric HCC it is necessary to continue the investigations in international research groups.

печеньгепатоцеллюлярная карциномадетидетская онкологияопухоли печени у детейliverhepatocellular carcinomachildrenpediatric oncologypediatric liver tumorsReferencesStuver S., Trichopoulos D. Cancer of the liver and biliary tract. In: Adami H.O., Hunter D., Trichopoulos D., editors. Textbook of Cancer Epidemiology. 2nd ed. NewYork: Oxford University Press; 2008. P. 308–332.Stuver S., Trichopoulos D. Cancer of the liver and biliary tract. In: Adami H.O., Hunter D., Trichopoulos D., editors. Textbook of Cancer Epidemiology. 2nd ed. NewYork: Oxford University Press; 2008. P. 308–332.Tang A., Hallouch O., Chernyak V., Kamaya A., Sirlin C.B. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom. Radiol. (NY). 2018; 43 (1): 13–25. https://doi.org/10.1007/s00261-017-1209-1.Tang A., Hallouch O., Chernyak V., Kamaya A., Sirlin C.B. Epidemiology of hepatocellular carcinoma: target population for surveillance and diagnosis. Abdom. Radiol. (NY). 2018; 43 (1): 13–25. https://doi.org/10.1007/s00261-017-1209-1.World Health Organization, I.A.f.R.o.C. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available from: https://www.iarc.fr/news-events/latest-worldcancer-statistics-globocan-2012-estimated-cancer-incidencemortality-and-prevalence-worldwide-in-2012/ (дата обращения: 06.05.2020).World Health Organization, I.A.f.R.o.C. Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available from: https://www.iarc.fr/news-events/latest-worldcancer-statistics-globocan-2012-estimated-cancer-incidencemortality-and-prevalence-worldwide-in-2012/ (дата обращения: 06.05.2020).SEER Cancer Statistics Factsheets: Liver and Intrahepatic Bile Duct Cancer. National Cancer Institute. 2014. [Last accessed on 2017 Apr]. Available from: https://seer.cancer.gov/statfacts/html/livibd.html (дата обращения: 06.05.2020).SEER Cancer Statistics Factsheets: Liver and Intrahepatic Bile Duct Cancer. National Cancer Institute. 2014. [Last accessed on 2017 Apr]. Available from: https://seer.cancer.gov/statfacts/html/livibd.html (дата обращения: 06.05.2020).Ghouri Y.A., Mian I., Rowe J.H. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J. Carcinog. 2017; 16: 1. https://doi.org/10.4103/jcar.JCar_9_16.Ghouri Y.A., Mian I., Rowe J.H. Review of hepatocellular carcinoma: epidemiology, etiology, and carcinogenesis. J. Carcinog. 2017; 16: 1. https://doi.org/10.4103/jcar.JCar_9_16.Czauderna P., Mackinlay G., Perilongo G., Brown J., Shafford E., Aronson D., Pritchard J., Chapchap P., Keeling J., Plaschkes J., Otte J.B. Liver Tumors Study Group of the International Society of Pediatric Oncology. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J. Clin. Oncol. 2002; 20 (12): 2798–2804. https://doi.org/10.1200/JCO.2002.06.102.Czauderna P., Mackinlay G., Perilongo G., Brown J., Shafford E., Aronson D., Pritchard J., Chapchap P., Keeling J., Plaschkes J., Otte J.B. Liver Tumors Study Group of the International Society of Pediatric Oncology. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J. Clin. Oncol. 2002; 20 (12): 2798–2804. https://doi.org/10.1200/JCO.2002.06.102.McGlynn K.A., London W.T. The global epidemiology of hepatocellular carcinoma: present and future. Clin. Liver Dis. 2011; 15 (2): 223–243. vii-x. https://doi.org/10.1016/j.cld.2011.03.006.McGlynn K.A., London W.T. The global epidemiology of hepatocellular carcinoma: present and future. Clin. Liver Dis. 2011; 15 (2): 223–243. vii-x. https://doi.org/10.1016/j.cld.2011.03.006.Czauderna P. Adult type vs. Childhood hepatocellular carcinoma – are they the same or different lesions? Biology, natural history, prognosis, and treatment. Med. Pediatr. Oncol. 2002; 39 (5): 519–523. https://doi.org/10.1002/mpo.10178.Czauderna P. Adult type vs. Childhood hepatocellular carcinoma – are they the same or different lesions? Biology, natural history, prognosis, and treatment. Med. Pediatr. Oncol. 2002; 39 (5): 519–523. https://doi.org/10.1002/mpo.10178.El-Serag H.B. Hepatocellular carcinoma. N. Engl. J. Med. 2011; 365 (12): 1118–1127. https://doi.org/10.1056/NEJMra1001683.El-Serag H.B. Hepatocellular carcinoma. N. Engl. J. Med. 2011; 365 (12): 1118–1127. https://doi.org/10.1056/NEJMra1001683.Kelly D., Sharif K., Brown R.M., Morland B. Hepatocellular carcinoma in children. Clin. Liver Dis. 2015; 19 (2): 433–447. https://doi.org/10.1016/j.cld.2015.01.010.Kelly D., Sharif K., Brown R.M., Morland B. Hepatocellular carcinoma in children. Clin. Liver Dis. 2015; 19 (2): 433–447. https://doi.org/10.1016/j.cld.2015.01.010.Lau C.S., Mahendraraj K., Chamberlain R.S. Hepatocellular carcinoma in the pediatric population: a population based clinical outcomes study involving 257 patients from the Surveillance, Epidemiology, and End Result (SEER) database (1973–2011). HPB Surg. 2015; 2015: 670728. https://doi.org/10.1155/2015/670728.Lau C.S., Mahendraraj K., Chamberlain R.S. Hepatocellular carcinoma in the pediatric population: a population based clinical outcomes study involving 257 patients from the Surveillance, Epidemiology, and End Result (SEER) database (1973–2011). HPB Surg. 2015; 2015: 670728. https://doi.org/10.1155/2015/670728.Litten J.B., Tomlinson G.E. Liver tumors in children. Oncologist. 2008; 13 (7): 812–820. https://doi.org/10.1634/theoncologist.2008-0011.Litten J.B., Tomlinson G.E. Liver tumors in children. Oncologist. 2008; 13 (7): 812–820. https://doi.org/10.1634/theoncologist.2008-0011.Otte J.B. Progress in the surgical treatment of malignant liver tumors in children. Cancer Treat. Rev. 2010; 36 (4): 360–371. https://doi.org/10.1016/j.ctrv.2010.02.013.Otte J.B. Progress in the surgical treatment of malignant liver tumors in children. Cancer Treat. Rev. 2010; 36 (4): 360–371. https://doi.org/10.1016/j.ctrv.2010.02.013.Darbari A., Sabin K.M., Shapiro C.N., Schwarz K.B. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology (Baltimore, Md). 2003; 38 (3): 560–566. https://doi.org/10.1053/jhep.2003.50375.Darbari A., Sabin K.M., Shapiro C.N., Schwarz K.B. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology (Baltimore, Md). 2003; 38 (3): 560–566. https://doi.org/10.1053/jhep.2003.50375.Buendia M.A. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Med. Pediatr. Oncol. 2002; 39 (5): 530–535. https://doi.org/10.1002/mpo.10180.Buendia M.A. Genetic alterations in hepatoblastoma and hepatocellular carcinoma: common and distinctive aspects. Med. Pediatr. Oncol. 2002; 39 (5): 530–535. https://doi.org/10.1002/mpo.10180.Katzenstein H.M., Krailo M.D., Malogolowkin M.H., Ortega J.A., Qu W., Douglass E.C., Feusner J.H., Reynolds M., Quinn J.J., Newman K., Finegold M.J., Haas J.E., Sensel M.G., Castleberry R.P., Bowman L.C. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer. 2003; 97 (8): 2006–2012. https://doi.org/10.1002/cncr.11292.Katzenstein H.M., Krailo M.D., Malogolowkin M.H., Ortega J.A., Qu W., Douglass E.C., Feusner J.H., Reynolds M., Quinn J.J., Newman K., Finegold M.J., Haas J.E., Sensel M.G., Castleberry R.P., Bowman L.C. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer. 2003; 97 (8): 2006–2012. https://doi.org/10.1002/cncr.11292.Aronson D.C., Meyers R.L. Malignant tumors of the liver in children. Semin. Pediatr. Surg. 2016; 25 (5): 265–275. https://doi.org/10.1053/j.sempedsurg.2016.09.002.Aronson D.C., Meyers R.L. Malignant tumors of the liver in children. Semin. Pediatr. Surg. 2016; 25 (5): 265–275. https://doi.org/10.1053/j.sempedsurg.2016.09.002.Weeda V.B., Aronson D.C., Verheij J., Lamers W.H. Is hepatocellular carcinoma the same disease in children and adults? Comparison of histology, molecular background, and treatment in pediatric and adult patients. Pediat. Blood Cancer. 2019; 66 (2): e27475. https://doi.org/10.1002/pbc.27475.Weeda V.B., Aronson D.C., Verheij J., Lamers W.H. Is hepatocellular carcinoma the same disease in children and adults? Comparison of histology, molecular background, and treatment in pediatric and adult patients. Pediat. Blood Cancer. 2019; 66 (2): e27475. https://doi.org/10.1002/pbc.27475.Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv. Anat. Pathol. 2007; 14 (3): 217–223. https://doi.org/10.1097/PAP.0b013e3180504913.Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv. Anat. Pathol. 2007; 14 (3): 217–223. https://doi.org/10.1097/PAP.0b013e3180504913.Prokurat A., Kluge P., Kosciesza A., Perek D., Kappeler A., Zimmermann A. Transitional liver cell tumors (TLCT) in older children and adolescents: a novel group of aggressive hepatic tumors expressing beta-catenin. Med. Pediatr. Oncol. 2002; 39 (5): 510–518. https://doi.org/10.1002/mpo.10177.Prokurat A., Kluge P., Kosciesza A., Perek D., Kappeler A., Zimmermann A. Transitional liver cell tumors (TLCT) in older children and adolescents: a novel group of aggressive hepatic tumors expressing beta-catenin. Med. Pediatr. Oncol. 2002; 39 (5): 510–518. https://doi.org/10.1002/mpo.10177.Eichenmüller M., Trippel F., Kreuder M., Beck A., Schwarzmayr T., Häberle B., Cairo S., Leuschner I., von Schweinitz D., Strom T.M., Kappler R. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J. Hepatol. 2014; 61 (6): 1312–1320. https://doi.org/10.1016/j.jhep.2014.08.009.Eichenmüller M., Trippel F., Kreuder M., Beck A., Schwarzmayr T., Häberle B., Cairo S., Leuschner I., von Schweinitz D., Strom T.M., Kappler R. The genomic landscape of hepatoblastoma and their progenies with HCC-like features. J. Hepatol. 2014; 61 (6): 1312–1320. https://doi.org/10.1016/j.jhep.2014.08.009.López-Terrada D., Alaggio R., de Dávila M.T., Czauderna P., Hiyama E., Katzenstein H., Leuschner I., Malogolowkin M., Meyers R., Ranganathan S., Tanaka Y., Tomlinson G., Fabrè M., Zimmermann A., Finegold M.J. Children's Oncology Group Liver Tumor Committee. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. Mod. Pathol. 2014; 27 (3): 472–491. https://doi.org/10.1038/modpathol.2013.80.López-Terrada D., Alaggio R., de Dávila M.T., Czauderna P., Hiyama E., Katzenstein H., Leuschner I., Malogolowkin M., Meyers R., Ranganathan S., Tanaka Y., Tomlinson G., Fabrè M., Zimmermann A., Finegold M.J. Children's Oncology Group Liver Tumor Committee. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium. Mod. Pathol. 2014; 27 (3): 472–491. https://doi.org/10.1038/modpathol.2013.80.Jain S., Singhal S., Lee P., Xu R. Molecular genetics of hepatocellular neoplasia. Am. J. Transl. Res. 2010; 2 (1): 105–118.Jain S., Singhal S., Lee P., Xu R. Molecular genetics of hepatocellular neoplasia. Am. J. Transl. Res. 2010; 2 (1): 105–118.Cieply B., Zeng G., Proverbs-Singh T., Geller D., Monga S. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology. 2009; 49 (3): 821–831. https://doi.org/10.1002/hep.22695.Cieply B., Zeng G., Proverbs-Singh T., Geller D., Monga S. Unique phenotype of hepatocellular cancers with exon-3 mutations in beta-catenin gene. Hepatology. 2009; 49 (3): 821–831. https://doi.org/10.1002/hep.22695.Yamaoka H., Ohtsu K., Sueda T., Yokoyama T., Hiyama E. Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors. Oncol. Rep. 2006; 15 (3): 551–556.Yamaoka H., Ohtsu K., Sueda T., Yokoyama T., Hiyama E. Diagnostic and prognostic impact of beta-catenin alterations in pediatric liver tumors. Oncol. Rep. 2006; 15 (3): 551–556.Vilarinho S., Erson-Omay E.Z., Harmanci A.S., Morotti R., Carrion-Grant G., Baranoski J., Knisely A.S., Ekong U., Emre S., Yasuno K., Bilguvar K., Günel M. Paediatric hepatocellular carcinoma due to somatic CTNNB1 and NFE2L2 mutations in the setting of inherited bi-allelic ABCB11 mutations. J. Hepatol. 2014; 61 (5): 1178–1183. https://doi.org/10.1016/j.jhep.2014.07.003.Vilarinho S., Erson-Omay E.Z., Harmanci A.S., Morotti R., Carrion-Grant G., Baranoski J., Knisely A.S., Ekong U., Emre S., Yasuno K., Bilguvar K., Günel M. Paediatric hepatocellular carcinoma due to somatic CTNNB1 and NFE2L2 mutations in the setting of inherited bi-allelic ABCB11 mutations. J. Hepatol. 2014; 61 (5): 1178–1183. https://doi.org/10.1016/j.jhep.2014.07.003.Chu J.S., Ge F.J., Zhang B., Wang Y., Silvestris N., Liu L.J., Zhao C.H., Lin L., Brunetti A.E., Fu Y.L., Wang J., Paradiso A., Xu J.M. Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 2013; 32 (1): 16. https://doi.org/10.1186/1756-9966-32-16.Chu J.S., Ge F.J., Zhang B., Wang Y., Silvestris N., Liu L.J., Zhao C.H., Lin L., Brunetti A.E., Fu Y.L., Wang J., Paradiso A., Xu J.M. Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 2013; 32 (1): 16. https://doi.org/10.1186/1756-9966-32-16.Park W.S., Dong S.M., Kim S.Y., Na E.Y., Shin M.S., Pi J.H., Kim B.J., Bae J.H., Hong Y.K., Lee K.S., Lee S.H., Yoo N.J., Jang J.J., Pack S., Zhuang Z., Schmidt L., Zbar B., Lee J.Y. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 1999; 59 (2): 307–310.Park W.S., Dong S.M., Kim S.Y., Na E.Y., Shin M.S., Pi J.H., Kim B.J., Bae J.H., Hong Y.K., Lee K.S., Lee S.H., Yoo N.J., Jang J.J., Pack S., Zhuang Z., Schmidt L., Zbar B., Lee J.Y. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 1999; 59 (2): 307–310.Chen J., Wang Q., Fu X., Huang X.H., Chen X.L., Cao L.Q., Chen L.Z., Tan H.X., Li W., Bi J., Zhang L.J. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol. Res. 2009; 39 (2): 177–186. https://doi.org/10.1111/j.1872-034X.2008.00449.x.Chen J., Wang Q., Fu X., Huang X.H., Chen X.L., Cao L.Q., Chen L.Z., Tan H.X., Li W., Bi J., Zhang L.J. Involvement of PI3K/PTEN/AKT/mTOR pathway in invasion and metastasis in hepatocellular carcinoma: association with MMP-9. Hepatol. Res. 2009; 39 (2): 177–186. https://doi.org/10.1111/j.1872-034X.2008.00449.x.Soini T., Haveri H., Elo J., Kauppinen M., Kyrönlahti A., Salo M.K., Lohi J., Andersson L.C., Wilson D.B., Heikinheimo M. Transcription factor GATA-4 is abundantly expressed in childhood but not in adult liver tumors. J. Pediatr. Gastroenterol. 2012; 54 (1): 101–108. https://doi.org/10.1097/MPG.0b013e31822d52cf.Soini T., Haveri H., Elo J., Kauppinen M., Kyrönlahti A., Salo M.K., Lohi J., Andersson L.C., Wilson D.B., Heikinheimo M. Transcription factor GATA-4 is abundantly expressed in childhood but not in adult liver tumors. J. Pediatr. Gastroenterol. 2012; 54 (1): 101–108. https://doi.org/10.1097/MPG.0b013e31822d52cf.Cornella H., Sayols S., Zhang Z., Hao K., Cabellos L., Hoshida Y. Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology. 2015; 148 (4): 806–818. e10. https://doi.org/10.1053/j.gastro.2014.12.028.Cornella H., Sayols S., Zhang Z., Hao K., Cabellos L., Hoshida Y. Unique genomic profile of fibrolamellar hepatocellular carcinoma. Gastroenterology. 2015; 148 (4): 806–818. e10. https://doi.org/10.1053/j.gastro.2014.12.028.Honeyman J.N., Simon E.P., Robine N., Chiaroni-Clarke R., Darcy D.G., Lim I.I., Gleason C.E., Murphy J.M., Rosenberg B.R., Teegan L., Takacs C.N., Botero S., Belote R., Germer S., Emde A.K., Vacic V., Bhanot U., LaQuaglia M.P., Simon S.M. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014; 343 (6174): 1010–1014. https://doi.org/10.1126/science.1249484.Honeyman J.N., Simon E.P., Robine N., Chiaroni-Clarke R., Darcy D.G., Lim I.I., Gleason C.E., Murphy J.M., Rosenberg B.R., Teegan L., Takacs C.N., Botero S., Belote R., Germer S., Emde A.K., Vacic V., Bhanot U., LaQuaglia M.P., Simon S.M. Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. Science. 2014; 343 (6174): 1010–1014. https://doi.org/10.1126/science.1249484.Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., Lee W., Yuan J., Wong P., Ho T.S., Miller M.L., Rekhtman N., Moreira A.L., Ibrahim F., Bruggeman C., Gasmi B., Zappasodi R., Maeda Y., Sander C., Garon E.B., Merghoub T., Wolchok J.D., Schumacher T.N., Chan T.A. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348 (6230): 124–128. https://doi.org/10.1126/science.aaa1348.Rizvi N.A., Hellmann M.D., Snyder A., Kvistborg P., Makarov V., Havel J.J., Lee W., Yuan J., Wong P., Ho T.S., Miller M.L., Rekhtman N., Moreira A.L., Ibrahim F., Bruggeman C., Gasmi B., Zappasodi R., Maeda Y., Sander C., Garon E.B., Merghoub T., Wolchok J.D., Schumacher T.N., Chan T.A. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348 (6230): 124–128. https://doi.org/10.1126/science.aaa1348.Chan T.A., Yarchoan M., Jaffee E., Swanton C., Quezada S.A., Stenzinger A., Peters S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol. 2019; 30 (1): 44–56. https://doi.org/10.1093/annonc/mdy495.Chan T.A., Yarchoan M., Jaffee E., Swanton C., Quezada S.A., Stenzinger A., Peters S. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann. Oncol. 2019; 30 (1): 44–56. https://doi.org/10.1093/annonc/mdy495.Ang C., Klempner S.J., Ali S.M., Madison R., Ross J.S., Severson E.A., Fabrizio D., Goodman A., Kurzrock R., Suh J., Millis S.Z. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 2019; 10 (40): 4018–4025. https://doi.org/10.18632/oncotarget.26998.Ang C., Klempner S.J., Ali S.M., Madison R., Ross J.S., Severson E.A., Fabrizio D., Goodman A., Kurzrock R., Suh J., Millis S.Z. Prevalence of established and emerging biomarkers of immune checkpoint inhibitor response in advanced hepatocellular carcinoma. Oncotarget. 2019; 10 (40): 4018–4025. https://doi.org/10.18632/oncotarget.26998.Shrestha R., Prithviraj P., Anaka M., Bridle K.R., Crawford D., Dhungel B., Steel J.C., Jayachandran A. Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma. Front. Oncol. 2018; 8: 269. https://doi.org/10.3389/fonc.2018.00269.Shrestha R., Prithviraj P., Anaka M., Bridle K.R., Crawford D., Dhungel B., Steel J.C., Jayachandran A. Monitoring immune checkpoint regulators as predictive biomarkers in hepatocellular carcinoma. Front. Oncol. 2018; 8: 269. https://doi.org/10.3389/fonc.2018.00269.Murawski M., Weeda V.B., Maibach R., Morland B., Roebuck D.J., Zimmerman A., Casanova M., Perilongo G., Laithier V., Kebudi R., Scopinaro M.J., Shun A., Brichard B., de Camargo B., Childs M., Aronson D.C., Czauderna P. Hepatocellular carcinoma in children: does modified platinumand doxorubicin-based chemotherapy increase tumor resectability and change outcome? Lessons learned from the SIOPEL 2 and 3 studies. J. Clin. Oncol. 2016; 34 (10): 1050–1056. https://doi.org/10.1200/JCO.2014.60.2250.Murawski M., Weeda V.B., Maibach R., Morland B., Roebuck D.J., Zimmerman A., Casanova M., Perilongo G., Laithier V., Kebudi R., Scopinaro M.J., Shun A., Brichard B., de Camargo B., Childs M., Aronson D.C., Czauderna P. Hepatocellular carcinoma in children: does modified platinumand doxorubicin-based chemotherapy increase tumor resectability and change outcome? Lessons learned from the SIOPEL 2 and 3 studies. J. Clin. Oncol. 2016; 34 (10): 1050–1056. https://doi.org/10.1200/JCO.2014.60.2250.Schmid I., Albert M.H., Haberle B. HB99-Hepatozellulare Karzinome: Behandlungsergebnisse und neueKonzepte. Monatsschr. Kinderheilkd. 2008; 156: 412.Schmid I., Albert M.H., Haberle B. HB99-Hepatozellulare Karzinome: Behandlungsergebnisse und neueKonzepte. Monatsschr. Kinderheilkd. 2008; 156: 412.Katzenstein H.M., Krailo M.D., Malogolowkin M.H., Ortega J.A., Liu-Mares W., Douglass E.C., Feusner J.H., Reynolds M., Quinn J.J., Newman K., Finegold M.J., Haas J.E., Sensel M.G., Castleberry R.P., Bowman L.C. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children’s Cancer Group intergroup study. J. Clin. Oncol. 2002; 20 (12): 2789–2797. https://doi.org/10.1200/JCO.2002.06.155.Katzenstein H.M., Krailo M.D., Malogolowkin M.H., Ortega J.A., Liu-Mares W., Douglass E.C., Feusner J.H., Reynolds M., Quinn J.J., Newman K., Finegold M.J., Haas J.E., Sensel M.G., Castleberry R.P., Bowman L.C. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children’s Cancer Group intergroup study. J. Clin. Oncol. 2002; 20 (12): 2789–2797. https://doi.org/10.1200/JCO.2002.06.155.Paediatric Hepatic International Tumour Trial (PHITT) https://clinicaltrials.gov/ct2/show/NCT03017326 (дата обращения: 06.05.2020).Paediatric Hepatic International Tumour Trial (PHITT) https://clinicaltrials.gov/ct2/show/NCT03017326 (дата обращения: 06.05.2020).Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Häussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359 (4): 378–390. https://doi.org/10.1056/NEJMoa0708857.Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., de Oliveira A.C., Santoro A., Raoul J.L., Forner A., Schwartz M., Porta C., Zeuzem S., Bolondi L., Greten T.F., Galle P.R., Seitz J.F., Borbath I., Häussinger D., Giannaris T., Shan M., Moscovici M., Voliotis D., Bruix J. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 2008; 359 (4): 378–390. https://doi.org/10.1056/NEJMoa0708857.Abou-Alfa G.K., Johnson P., Knox J.J., Capanu M., Davidenko I., Lacava J., Leung T., Gansukh B., Saltz L.B. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010; 304 (19): 2154–2160. https://doi.org/10.1001/jama.2010.1672.Abou-Alfa G.K., Johnson P., Knox J.J., Capanu M., Davidenko I., Lacava J., Leung T., Gansukh B., Saltz L.B. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA. 2010; 304 (19): 2154–2160. https://doi.org/10.1001/jama.2010.1672.Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., Luo R., Feng J., Ye S., Yang T.S., Xu J., Sun Y., Liang H., Liu J., Wang J., Tak W.Y., Pan H., Burock K., Zou J., Voliotis D., Guan Z. Efficacy and safety of sorafenib in patients in the AsiaPacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10 (1): 25–34. https://doi.org/10.1016/S1470-2045(08)70285-7.Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., Luo R., Feng J., Ye S., Yang T.S., Xu J., Sun Y., Liang H., Liu J., Wang J., Tak W.Y., Pan H., Burock K., Zou J., Voliotis D., Guan Z. Efficacy and safety of sorafenib in patients in the AsiaPacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009; 10 (1): 25–34. https://doi.org/10.1016/S1470-2045(08)70285-7.Ganten T.M., Stauber R.E., Schott E., Malfertheiner P., Buder R., Galle P.R., Göhler T., Walther M., Koschny R., Gerken G. Sorafenib in patients with hepatocellular carcinoma – results of the observational INSIGHT study. Clin. Cancer Res. 2017; 23 (19): 5720–5728. https://doi.org/10.1158/1078-0432.CCR-16-0919.Ganten T.M., Stauber R.E., Schott E., Malfertheiner P., Buder R., Galle P.R., Göhler T., Walther M., Koschny R., Gerken G. Sorafenib in patients with hepatocellular carcinoma – results of the observational INSIGHT study. Clin. Cancer Res. 2017; 23 (19): 5720–5728. https://doi.org/10.1158/1078-0432.CCR-16-0919.Schmid I., Häberle B., Albert M.H., Corbacioglu S., Fröhlich B., Graf N., Kammer B., Kontny U., Leuschner I., ScheelWalter H.G., Scheurlen W., Werner S., Wiesel T., von Schweinitz D. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr. Blood Cancer. 2012; 58 (4): 539–544. https://doi.org/10.1002/pbc.23295.Schmid I., Häberle B., Albert M.H., Corbacioglu S., Fröhlich B., Graf N., Kammer B., Kontny U., Leuschner I., ScheelWalter H.G., Scheurlen W., Werner S., Wiesel T., von Schweinitz D. Sorafenib and cisplatin/doxorubicin (PLADO) in pediatric hepatocellular carcinoma. Pediatr. Blood Cancer. 2012; 58 (4): 539–544. https://doi.org/10.1002/pbc.23295.Schmid I., von Schweinitz D. Pediatric hepatocellular carcinoma: challenges and solutions. J. Hepatocell. Carcinoma. 2017; 4: 15–21. https://doi.org/10.2147/JHC.S94008.Schmid I., von Schweinitz D. Pediatric hepatocellular carcinoma: challenges and solutions. J. Hepatocell. Carcinoma. 2017; 4: 15–21. https://doi.org/10.2147/JHC.S94008.Kudo M., Finn R.S., Qin S., Han K.H., Ikeda K., Piscaglia F., Baron A., Park J.W., Han G., Jassem J., Blanc J.F., Vogel A., Komov D., Evans J., Lopez C., Dutcus C., Guo M., Saito K., Kraljevic S., Tamai T., Ren M., Cheng A.L. Lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 trial. Lancet. 2018; 391 (10126): 1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1.Kudo M., Finn R.S., Qin S., Han K.H., Ikeda K., Piscaglia F., Baron A., Park J.W., Han G., Jassem J., Blanc J.F., Vogel A., Komov D., Evans J., Lopez C., Dutcus C., Guo M., Saito K., Kraljevic S., Tamai T., Ren M., Cheng A.L. Lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 trial. Lancet. 2018; 391 (10126): 1163–1173. https://doi.org/10.1016/S0140-6736(18)30207-1.Bruix J., Qin S., Merle P., Granito A., Huang Y.H., Bodoky G., Pracht M., Yokosuka O., Rosmorduc O., Breder V., Gerolami R., Masi G., Ross P.J., Song T., Bronowicki J.P., OllivierHourmand I., Kudo M., Cheng A.L., Llovet J.M., Finn R.S., LeBerre M.A., Baumhauer A., Meinhardt G., Han G. RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389 (10064): 56–66. https://doi.org/10.1016/S0140-6736(16)32453-9.Bruix J., Qin S., Merle P., Granito A., Huang Y.H., Bodoky G., Pracht M., Yokosuka O., Rosmorduc O., Breder V., Gerolami R., Masi G., Ross P.J., Song T., Bronowicki J.P., OllivierHourmand I., Kudo M., Cheng A.L., Llovet J.M., Finn R.S., LeBerre M.A., Baumhauer A., Meinhardt G., Han G. RESORCE Investigators. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017; 389 (10064): 56–66. https://doi.org/10.1016/S0140-6736(16)32453-9.Abou-Alfa G.K., Meyer T., Cheng A.L., El-Khoueiry A.B., Rimassa L., Ryoo B.Y., Cicin I., Merle P., Chen Y., Park J.W., Blanc J.F., Bolondi L., Klümpen H.J., Chan S.L., Zagonel V., Pressiani T., Ryu M.H., Venook A.P., Hessel C., BorgmanHagey A.E., Schwab G., Kelley R.K. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 2018; 379 (1): 54–63. https://doi.org/10.1056/NEJMoa1717002.Abou-Alfa G.K., Meyer T., Cheng A.L., El-Khoueiry A.B., Rimassa L., Ryoo B.Y., Cicin I., Merle P., Chen Y., Park J.W., Blanc J.F., Bolondi L., Klümpen H.J., Chan S.L., Zagonel V., Pressiani T., Ryu M.H., Venook A.P., Hessel C., BorgmanHagey A.E., Schwab G., Kelley R.K. Cabozantinib in patients with advanced and progressing hepatocellular carcinoma. N. Engl. J. Med. 2018; 379 (1): 54–63. https://doi.org/10.1056/NEJMoa1717002.Zhu A.X., Park J.O., Ryoo B.Y., Yen C.J., Poon R., Pastorelli D., Blanc J.F., Chung H.C., Baron A.D., Pfiffer T.E., Okusaka T., Kubackova K., Trojan J., Sastre J., Chau I., Chang S.C., Abada P.B., Yang L., Schwartz J.D., Kudo M. REACH Trial Investigators. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015; 16 (7): 859–870. https://doi.org/10.1016/S1470-2045(15)00050-9.Zhu A.X., Park J.O., Ryoo B.Y., Yen C.J., Poon R., Pastorelli D., Blanc J.F., Chung H.C., Baron A.D., Pfiffer T.E., Okusaka T., Kubackova K., Trojan J., Sastre J., Chau I., Chang S.C., Abada P.B., Yang L., Schwartz J.D., Kudo M. REACH Trial Investigators. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol. 2015; 16 (7): 859–870. https://doi.org/10.1016/S1470-2045(15)00050-9.Kudo M. Targeted and immune therapies for hepatocellular carcinoma: predictions for 2019 and beyond. World J. Gastroenterol. 2019; 25 (7): 789–807. https://doi.org/10.3748/wjg.v25.i7.789.Kudo M. Targeted and immune therapies for hepatocellular carcinoma: predictions for 2019 and beyond. World J. Gastroenterol. 2019; 25 (7): 789–807. https://doi.org/10.3748/wjg.v25.i7.789.Kudo M. Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials. Oncology. 2017; 92 (Suppl 1): 50–62. https://doi.org/10.1159/000451016.Kudo M. Immune checkpoint inhibition in hepatocellular carcinoma: basics and ongoing clinical trials. Oncology. 2017; 92 (Suppl 1): 50–62. https://doi.org/10.1159/000451016.Zhu A.X., Finn R.S., Edeline J., Cattan S., Ogasawara S., Palmer D. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19 (7): 940–952. https://doi.org/10.1016/S1470-2045(18)30351-6.Zhu A.X., Finn R.S., Edeline J., Cattan S., Ogasawara S., Palmer D. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. Lancet Oncol. 2018; 19 (7): 940–952. https://doi.org/10.1016/S1470-2045(18)30351-6.Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma https://clinicaltrials.gov/ct2/show/NCT04134559 (дата обращения: 06.05.2020).Checkpoint Inhibition In Pediatric Hepatocellular Carcinoma https://clinicaltrials.gov/ct2/show/NCT04134559 (дата обращения: 06.05.2020).Zhou F., Shang W., Yu X., Tian J. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med. Res. Rev. 2018; 38 (2): 741–767. https://doi.org/10.1002/med.21455.Zhou F., Shang W., Yu X., Tian J. Glypican-3: a promising biomarker for hepatocellular carcinoma diagnosis and treatment. Med. Res. Rev. 2018; 38 (2): 741–767. https://doi.org/10.1002/med.21455.El-Saadany S., El-Demerdash T., Helmy A., Mayah W.W., El-Sayed H.B., Hassanien M., Elmashad N., Fouad M.A., Basha E.A. Diagnostic value of Glypican-3 for hepatocellular carcinomas. Asian Pac. J. Cancer Prev. APJCP. 2018; 19 (3): 811–817. https://doi.org/10.22034/APJCP.2018.19.3.811.El-Saadany S., El-Demerdash T., Helmy A., Mayah W.W., El-Sayed H.B., Hassanien M., Elmashad N., Fouad M.A., Basha E.A. Diagnostic value of Glypican-3 for hepatocellular carcinomas. Asian Pac. J. Cancer Prev. APJCP. 2018; 19 (3): 811–817. https://doi.org/10.22034/APJCP.2018.19.3.811.Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) https://clinicaltrials.gov/ct2/show/NCT02905188 (дата обращения: 06.05.2020).Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells for Hepatocellular Carcinoma (GLYCAR) https://clinicaltrials.gov/ct2/show/NCT02905188 (дата обращения: 06.05.2020).Allan B.J., Wang B., Davis J.S., Parikh P.P., Perez E.A., Neville H.L., Sola J.E. A review of 218 pediatric cases of hepatocellular carcinoma. J. Pediatr. Surg. 2014; 49 (1): 166–171; discussion 171. https://doi.org/10.1016/j.jpedsurg.2013.09.050.Allan B.J., Wang B., Davis J.S., Parikh P.P., Perez E.A., Neville H.L., Sola J.E. A review of 218 pediatric cases of hepatocellular carcinoma. J. Pediatr. Surg. 2014; 49 (1): 166–171; discussion 171. https://doi.org/10.1016/j.jpedsurg.2013.09.050.Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., Montalto F., Ammatuna M., Morabito A., Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996; 334 (11): 693–699. https://doi.org/10.1056/NEJM199603143341104.Mazzaferro V., Regalia E., Doci R., Andreola S., Pulvirenti A., Bozzetti F., Montalto F., Ammatuna M., Morabito A., Gennari L. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N. Engl. J. Med. 1996; 334 (11): 693–699. https://doi.org/10.1056/NEJM199603143341104.Zhu Z. Milan criteria and its expansions in liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg. Nutr. 2016; 5 (6): 498–502. https://doi.org/10.21037/hbsn.2016.12.09.Zhu Z. Milan criteria and its expansions in liver transplantation for hepatocellular carcinoma. Hepatobiliary Surg. Nutr. 2016; 5 (6): 498–502. https://doi.org/10.21037/hbsn.2016.12.09.De Ville G.J., Meyers R.L., Tiao G.M., Morland B. Beyond the Milan criteria for liver transplantation in children with hepatic tumours. Lancet Gastroenterol. Hepatol. 2017; 2 (6): 456–462. https://doi.org/10.1016/s2468-1253(17)30084-5.De Ville G.J., Meyers R.L., Tiao G.M., Morland B. Beyond the Milan criteria for liver transplantation in children with hepatic tumours. Lancet Gastroenterol. Hepatol. 2017; 2 (6): 456–462. https://doi.org/10.1016/s2468-1253(17)30084-5.Squires R.H., Ng V., Romero R., Ekong U., Hardikar W., Emre S., Mazariegos G.V. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology. Hepatology. 2014; 60 (1): 362–398. https://doi.org/10.1002/hep.27191.Squires R.H., Ng V., Romero R., Ekong U., Hardikar W., Emre S., Mazariegos G.V. Evaluation of the pediatric patient for liver transplantation: 2014 practice guideline by the American Association for the Study of Liver Diseases, American Society of Transplantation and the North American Society for Pediatric Gastroenterology, Hepatology. Hepatology. 2014; 60 (1): 362–398. https://doi.org/10.1002/hep.27191.Malek M.M., Shah S.R., Atri P., Paredes J.L., DiCicco L.A., Sindhi R., Soltys K.A., Mazariegos G.V., Kane T.D. Review of outcomes of primary liver cancers in children: our institutional experience with resection and transplantation. Surgery. 2010; 148 (4): 778–782. https://doi.org/10.1016/j.surg.2010.07.021.Malek M.M., Shah S.R., Atri P., Paredes J.L., DiCicco L.A., Sindhi R., Soltys K.A., Mazariegos G.V., Kane T.D. Review of outcomes of primary liver cancers in children: our institutional experience with resection and transplantation. Surgery. 2010; 148 (4): 778–782. https://doi.org/10.1016/j.surg.2010.07.021.Beaunoyer M., Vanatta J.M., Ogihara M., Strichartz D., Dahl G., Berquist W.E., Castillo R.O., Cox K.L., Esquivel C.O. Outcomes of transplantation in children with primary hepatic malignancy. Pediatr. Transplant. 2007; 11 (6): 655–660. https://doi.org/10.1111/j.1399-3046.2007.00751.x.Beaunoyer M., Vanatta J.M., Ogihara M., Strichartz D., Dahl G., Berquist W.E., Castillo R.O., Cox K.L., Esquivel C.O. Outcomes of transplantation in children with primary hepatic malignancy. Pediatr. Transplant. 2007; 11 (6): 655–660. https://doi.org/10.1111/j.1399-3046.2007.00751.x.Ismail H., Broniszczak D., Kaliciński P. Liver transplantation in children with hepatocellular carcinoma Do Milan criteria apply to pediatric patients? Pediatr. Transplant. 2009; 13 (6): 682–692. https://doi.org/10.1111/j.1399-3046.2009.01062.x.Ismail H., Broniszczak D., Kaliciński P. Liver transplantation in children with hepatocellular carcinoma Do Milan criteria apply to pediatric patients? Pediatr. Transplant. 2009; 13 (6): 682–692. https://doi.org/10.1111/j.1399-3046.2009.01062.x.Kosola S., Lauronen J., Sairanen H. High survival rates after liver transplantation for hepatoblastoma and hepatocellular carcinoma. Pediatr. Transplant. 2010; 14 (5): 646–650. https://doi.org/10.1111/j.1399-3046.2010.01312.x.Kosola S., Lauronen J., Sairanen H. High survival rates after liver transplantation for hepatoblastoma and hepatocellular carcinoma. Pediatr. Transplant. 2010; 14 (5): 646–650. https://doi.org/10.1111/j.1399-3046.2010.01312.x.McAteer J.P., Goldin A.B., Healey P.J., Gow K.W. Surgical treatment of primary liver tumors in children: outcomes analysis of resection and transplantation in the SEER database. Pediatr. Transplant. 2013; 17 (8): 744–750. https://doi.org/10.1111/petr.12144.McAteer J.P., Goldin A.B., Healey P.J., Gow K.W. Surgical treatment of primary liver tumors in children: outcomes analysis of resection and transplantation in the SEER database. Pediatr. Transplant. 2013; 17 (8): 744–750. https://doi.org/10.1111/petr.12144.

The authors declare that there are no conflicts of interest present.